文献速递瓣膜外科

经导管瓣中瓣与再次外科主动脉瓣置换治疗衰败支架生物瓣的比较

Transcatheter Valve-in-Valve Vs Surgical Replacement of Failing Stented Aortic Biological Valves.
PubMed 文献 · Ann Thorac Surg · 2019-05-02

该回顾性研究比较了350例因支架主动脉生物瓣衰败行再次置换的患者,其中TAVI-in-valve 90例、再次SAVR 260例。两组手术死亡率与中期死亡率相似,但TAVI-in-valve严重患者-人工瓣膜不匹配更常见,SAVR血流动力学更优。

要点

  • TAVI-in-valve与再次SAVR手术死亡率和中期死亡率相似
  • TAVI-in-valve严重患者-人工瓣膜不匹配发生率更高(44% vs 12%)
  • SAVR血流动力学更优,可能为优选方案

核心结论

  • TAVI-in-valve与再次SAVR手术死亡率和中期死亡率相似,但SAVR血流动力学更优,可能为优选方案。

研究设计与样本

  • 单中心回顾性队列研究,纳入2008年11月至2018年5月350例连续因支架主动脉生物瓣衰败行再次置换的患者,TAVI-in-valve 90例(26%),再次SAVR 260例(74%)。

主要发现

  • 患者年龄74岁(IQR 65-79),女性100例(29%),主动脉瓣内径21 mm(IQR 19-22),STS预测手术死亡风险4.1%(IQR 2.3%-6.8%),距再次手术间隔7年(IQR 5-11年)。

临床怎么用

  • 对于支架主动脉生物瓣衰败患者,TAVI-in-valve与再次SAVR均可考虑,两者手术及中期死亡率相似。
  • 需权衡TAVI-in-valve较高的严重患者-人工瓣膜不匹配风险与SAVR更优的血流动力学表现,个体化选择术式。

局限性

  • 单中心回顾性研究,样本量有限,随访时间较短(中位2.1年),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study directly compared outcomes of transcatheter aortic valve-in-valve insertion (TAVI-in-valve) with repeat surgical aortic valve replacement (SAVR) for failing stented aortic biological prostheses. METHODS: We retrospectively reviewed the records of 350 consecutive patients who underwent repeat aortic valve replacement of failing stented aortic biological valve prostheses at our institution between November 2008 and May 2018. Operations included TAVI-in-valve in 90 patients (26%) and repeat SAVR in 260 patients (74%). RESULTS: Patient age was 74 years (interquartile range [IQR], 65-79 years), 100 patients (29%) were women, aortic valve internal diameter was 21 mm (IQR, 19-22), Society of Thoracic Surgeons predicted operative mortality risk was 4.1% (IQR, 2.3%-6.8%), and the interval to repeat operation was 7 years (IQR, 5-11 years). A 23-mm or smaller valve was inserted in 57 patients (63%) in the TAVI-in-valve group and in 170 (65%) in the SAVR group (P = .725). Aortic root enlargement was done in 45 patients (17%) in the SAVR group. Procedure-related complications were less in the TAVI-in-valve group (23% vs SAVR 59%, P < .001), whereas operative mortality was similar in both groups (2.2% vs SAVR 2.6%, P = 1.000). Severe patient-to-prosthesis mismatch was more common after TAVI-in-valve (44% vs SAVR 12%, P < .001). Median duration of follow-up was 2.1 years (IQR, 1.2-4.2 years). Multivariable analysis demonstrated no association between TAVI-in-valve and intermediate-term mortality (hazard ratio, 1.18; 95% confidence interval, 0.62 to 2.22; P = .612). CONCLUSIONS: TAVI-in-valve and repeat SAVR can be done with similar operative and intermediate-term mortality. SAVR results in better hemodynamic function and thus appears the preferred option.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sedeek AF, Greason KL, Sandhu GS, et al. Transcatheter Valve-in-Valve Vs Surgical Replacement of Failing Stented Aortic Biological Valves. Ann Thorac Surg. 2019. PMID: 31055036. doi:10.1016/j.athoracsur.2019.03.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。